Kynos Therapeutics Announces Positive Top Line Results From the First-In-Human Phase I Study of its KMO Inhibitor, KNS366, Demonstrating Safety, Tolerability and Target Engagement
April 23, 2024
Edinburgh, UK – Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute and chronic inflammatory disorders,